NCT04086108

Brief Summary

In this four-way crossover study, a plasmakinetic profile of GABA from tomatoes as compared to a gamma-aminobutyric acid (GABA) supplement in healthy young men will be established. In addition, a plasmakinetic profiles of glutamate from a supplement and from tomatoes as well as the effects of glutamate from tomatoes and a supplement on the GABA plasma levels will be determined. This study will therefore provide information about the effect of a food matrix on GABA plasmakinetics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 11, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

November 4, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 5, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 5, 2019

Completed
Last Updated

January 21, 2020

Status Verified

January 1, 2020

Enrollment Period

1 month

First QC Date

June 18, 2019

Last Update Submit

January 17, 2020

Conditions

Keywords

GABAGlutamateTomatoPlasmakineticsBioavailability

Outcome Measures

Primary Outcomes (4)

  • Area under the plasma concentration versus time curve (AUC ) of plasma-time curves of GABA

    After intake of a GABA supplement and tomatoes.

    6 months

  • Peak Plasma Concentration (Cmax) of plasma-time curves of GABA

    After intake of a GABA supplement and tomatoes.

    6 months

  • Time to Peak Plasma Concentration (Tmax) of plasma-time curves of GABA

    After intake of a GABA supplement and tomatoes.

    6 months

  • Half-life (T1/2) of plasma-time curves of GABA

    After intake of a GABA supplement and tomatoes.

    6 months

Secondary Outcomes (8)

  • Area under the plasma concentration versus time curve (AUC) of plasma-time curves of glutamate

    6 months

  • Peak Plasma Concentration (Cmax) of plasma-time curves of glutamate

    6 months

  • Time to Peak Plasma Concentration (Tmax) of plasma-time curves of glutamate

    6 months

  • Half-life (T1/2) of plasma-time curves of glutamate

    6 months

  • Area under the plasma concentration versus time curve (AUC) AUC of plasma-time curves of GABA in response to a glutamate supplement.

    6 months

  • +3 more secondary outcomes

Study Arms (4)

Tomato

EXPERIMENTAL

Single oral administration

Dietary Supplement: Tomato

GABA supplement

EXPERIMENTAL

Single oral administration

Dietary Supplement: GABA supplement

Glutamate supplement

EXPERIMENTAL

Single oral administration

Dietary Supplement: Glutamate supplement

Placebo

NO INTERVENTION

Single oral administration, same volume of water that is distributed in the other arms

Interventions

TomatoDIETARY_SUPPLEMENT

A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.

Tomato
GABA supplementDIETARY_SUPPLEMENT

1 gram of GABA dissolved in water.

Also known as: Gamma-aminobutyric acid
GABA supplement
Glutamate supplementDIETARY_SUPPLEMENT

A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.

Glutamate supplement

Eligibility Criteria

Age18 Years - 28 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI between 18.5 and 25 kg/m2
  • Age is between 18 and 28 years
  • Good general health
  • Male
  • Veins suitable for blood sampling
  • Able to speak Dutch

You may not qualify if:

  • Is currently suffering from a disease including mental disorders
  • Has had any gastrointestinal condition/disease within the 3 months prior to the intervention
  • Haemoglobin (Hb) level \< 8.5 mmol/L
  • Has used medication in the two months before and/or during the intervention. Occasional use of NSAIDs or paracetamol (\<once a week on average) are is allowed.
  • Reported weight loss or weight gain of \> 2 kg in the month prior to the intervention
  • Use of dietary supplements, 3 weeks before-, or during the intervention.
  • Allergic to products that are provided as part of the standardised diet
  • Unwilling to consume the products that are part of the standardised diet
  • Allergic to tomatoes
  • (History of) drug abuse, in this case meaning \>1 x per month use of recreational drugs
  • Smoking
  • Alcohol consumption of \>10 standardised glasses per week.
  • Not able to refrain from alcohol consumption 2 days before each test day
  • Recent or planned blood donation (\<3 month prior to first study day or during intervention)
  • Personnel of Wageningen University, department of Human Nutrition and Health,
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wageningen University, Division of Human Nutrition

Wageningen, Netherlands

Location

Related Publications (1)

  • de Bie TH, Balvers MGJ, de Vos RCH, Witkamp RF, Jongsma MA. The influence of a tomato food matrix on the bioavailability and plasma kinetics of oral gamma-aminobutyric acid (GABA) and its precursor glutamate in healthy men. Food Funct. 2022 Aug 15;13(16):8399-8410. doi: 10.1039/d2fo01358d.

MeSH Terms

Interventions

gamma-Aminobutyric Acid

Intervention Hierarchy (Ancestors)

AminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Renger Witkamp, PhD

    Wageningen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: For the study, research subjects will visit the university on four test days separated by a wash out period of one week.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2019

First Posted

September 11, 2019

Study Start

November 4, 2019

Primary Completion

December 5, 2019

Study Completion

December 5, 2019

Last Updated

January 21, 2020

Record last verified: 2020-01

Locations